Troche vs Tablet: Understanding Ketamine Formulation Differences

What Are the Different Oral Ketamine Formulations?

When patients begin exploring at-home ketamine treatment for depression or chronic pain, they quickly encounter several terms: tablets, troches, lozenges, and sometimes rapid-dissolve tablets (RDTs). While all of these are oral formulations of ketamine, they differ in meaningful ways that can affect your treatment experience, absorption rates, and overall outcomes.

Understanding these differences empowers you to have more informed conversations with your prescribing clinician and helps set realistic expectations for your therapy. For a detailed explanation of how absorption works, see our article on bioavailability explained.

Ketamine Troches: What Are They?

A troche (pronounced "TRO-key") is a small, flavored lozenge typically compounded by a specialty pharmacy. Troches are designed to dissolve slowly in the mouth, usually between the cheek and gum or under the tongue. The ketamine is absorbed through the oral mucosa as the troche breaks down, bypassing first-pass metabolism in the liver.

How Troches Work

Troches are made by mixing ketamine hydrochloride into a base material, often a polyethylene glycol (PEG) or similar compound that forms a waxy, dissolvable matrix. The patient places the troche in their mouth and allows it to dissolve over 10 to 20 minutes. During this time, ketamine passes through the mucosal tissues and enters the bloodstream.

Advantages of Troches

• Widely available through compounding pharmacies
• Can be flavored to improve taste (ketamine has a notably bitter flavor)
• Allow for gradual absorption over a longer period

Limitations of Troches

• Dissolution time varies based on saliva production, temperature, and individual oral conditions
• Compounded formulations may have more batch-to-batch variability than manufactured tablets
• The extended dissolve time (sometimes exceeding 15 minutes) can be uncomfortable for some patients
• Excess saliva produced during dissolution can lead to swallowing the medication, reducing sublingual absorption

Ketamine Lozenges: Are They Different from Troches?

In practice, the terms "troche" and "lozenge" are often used interchangeably in the ketamine therapy space. Both refer to compounded oral formulations designed to dissolve in the mouth. However, there can be subtle differences depending on the compounding pharmacy.

Some pharmacies produce lozenges with a harder candy-like consistency, while troches tend to be softer and waxier. The key distinction is not in the name but in the base material, dissolution rate, and the specific compounding pharmacy's formulation process.

Regardless of whether your prescription says "troche" or "lozenge," the clinical goal is the same: deliver ketamine through the oral mucosa for sublingual or buccal absorption.

Ketamine Tablets: A Standardized Approach

Ketamine tablets represent a more standardized oral formulation. Unlike compounded troches, tablets can be manufactured with tighter controls over dose uniformity, dissolution characteristics, and shelf stability. Sublingual ketamine tablets are designed to dissolve under the tongue relatively quickly, typically within 5 to 10 minutes.

How Tablets Differ from Troches

The manufacturing process for tablets involves compression of powdered ketamine with excipients (inactive ingredients) that control how the tablet breaks down. This process allows for:

• Consistent dosing: Each tablet contains a precise amount of ketamine, with less variation between individual doses
• Predictable dissolution: Tablets are engineered to dissolve at a controlled rate
• Standardized quality control: Manufacturing follows established pharmaceutical protocols
• Shorter dissolve time: Many sublingual tablets dissolve faster than troches, reducing patient discomfort

Rapid-Dissolve Tablets (RDTs)

Some ketamine tablets are formulated as rapid-dissolve or orally disintegrating tablets. These are designed to break apart within seconds to a few minutes when placed under the tongue. RDTs maximize the surface area contact with oral mucosa, potentially improving absorption efficiency.

Bioavailability Comparison

Bioavailability refers to the percentage of a drug that reaches systemic circulation after administration. For oral ketamine formulations, bioavailability is a critical factor because it determines how much of the administered dose actually produces therapeutic effects.

These ranges are approximate and based on published pharmacokinetic studies. Individual results vary based on factors like mucosal health, saliva production, and whether the patient inadvertently swallows some of the dissolved medication.

The key takeaway is that all sublingual or buccal formulations significantly outperform simple oral (swallowed) administration because they bypass first-pass hepatic metabolism. When ketamine is swallowed and absorbed through the gastrointestinal tract, the liver metabolizes a substantial portion before it reaches systemic circulation.

Patient Experience: Practical Differences

Beyond pharmacokinetics, there are practical differences that affect day-to-day treatment.

Taste and Comfort

Ketamine has an inherently bitter, metallic taste. Troches and lozenges can be flavored (mint, citrus, berry) to mask this taste, but the extended dissolve time means patients are exposed to the flavor longer. Tablets, especially rapid-dissolve formulations, minimize taste exposure due to faster dissolution.

Saliva Management

A common challenge with troches is excess saliva production. As the troche dissolves, patients accumulate saliva mixed with dissolved ketamine. Swallowing this saliva routes the ketamine through the GI tract, reducing sublingual bioavailability. Some clinicians instruct patients to hold saliva in the mouth and then spit it out after the dissolution period, though this can reduce the total absorbed dose.

Tablets that dissolve more quickly produce less excess saliva, which can simplify the administration process.

Consistency Between Doses

Because compounded troches are made in smaller batches at individual pharmacies, there can be more variability between doses compared to manufactured tablets. This does not mean compounded formulations are unreliable, but patients who notice inconsistent effects between doses may benefit from discussing tablet alternatives with their clinician.

Which Formulation Is Right for You?

The choice between a troche, lozenge, or tablet depends on several factors that your prescribing clinician will consider:

• Treatment goals: The target dose and therapeutic window for your specific condition
• Tolerance and sensitivity: Patients new to ketamine may benefit from formulations that allow precise dose control
• Practical considerations: Your ability to hold a dissolving medication in your mouth for an extended period
• Insurance and cost: Compounded formulations and manufactured tablets may differ in cost and insurance coverage
• Availability: Not all pharmacies carry all formulations

It is important to note that switching formulations should always be done under medical guidance. Even if two formulations contain the same dose of ketamine, differences in bioavailability mean the effective dose reaching your bloodstream may change.

Compounding Quality and Regulation

Compounding pharmacies that produce ketamine troches and lozenges operate under state pharmacy board regulations and, in some cases, FDA oversight (particularly 503B outsourcing facilities). However, the regulatory framework for compounded medications differs from that of FDA-approved manufactured drugs.

Patients should ensure their compounding pharmacy:

• Is licensed and in good standing with their state pharmacy board
• Follows United States Pharmacopeia (USP) standards for compounding
• Provides certificates of analysis for potency and purity upon request
• Has a track record of reliability with their prescribing clinician

Manufactured ketamine tablets, when available through FDA-registered facilities, undergo more standardized quality testing including dissolution testing, content uniformity analysis, and stability studies.

The Future of Oral Ketamine Formulations

Research into optimized ketamine delivery continues to advance. Several pharmaceutical companies are developing proprietary oral ketamine formulations with improved bioavailability profiles. These include novel sublingual films, buccal patches, and engineered tablet formulations that aim to deliver more consistent plasma levels with lower total doses.

As the evidence base for ketamine therapy grows and more formulations reach the market, patients and clinicians will have increasingly refined options for matching the delivery method to the individual treatment plan.

Key Points to Discuss with Your Clinician

If you are currently using a troche or lozenge and are curious about tablet formulations, or vice versa, consider asking your clinician:

1. What is the expected bioavailability of my current formulation?
2. Would a different formulation improve consistency in my treatment response?
3. Are there cost differences between compounded and manufactured options?
4. How would switching formulations affect my current dosing protocol?

Open communication with your treatment team ensures that your formulation choice supports the best possible therapeutic outcomes.

References

• Pharmacokinetics of Ketamine and Metabolite Levels After Oral and Sublingual Administration — Published pharmacokinetic study comparing oral vs sublingual ketamine absorption routes
• Bioavailability of Intranasal, Sublingual, and Oral Ketamine — Comparative analysis of ketamine bioavailability across multiple administration routes
• FDA Information on Compounding — FDA guidance on the regulation of compounded medications
• United States Pharmacopeia (USP) Compounding Standards — Standards governing pharmacy compounding practices
• Sublingual Ketamine for Depression: A Review — Clinical review of sublingual ketamine formulations in depression treatment